Compare Moderna, Inc. (MRNA) vs Pinterest Inc (PINS) Price & Performance

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Pinterest (PINS) trades at $22.93, down 5.91% over 24 hours, reflecting market disappointment despite strong Q2 2026 earnings beats. Revenue growth remains robust at 18% year-over-year, driven by AI-powered ads and record user growth to 640 million monthly active users. Technical indicators show a bullish moving average signal but neutral oscillators, with key support at $23. Recent news highlights a federal securities lawsuit investigation and CFO stock sales, adding volatility.

The outlook is mixed: solid fundamentals and a $28.69 analyst price target suggest upside, but competitive ad markets and lukewarm Q3 guidance pose risks. Investor sentiment is cautious despite bullish analyst consensus, with the stock's high P/E ratio of 69.85 requiring sustained growth to justify valuations. Key opportunities lie in international expansion and AI monetization, while legal and competitive pressures are headwinds.